乳腺癌放疗联合曲妥珠单抗的心脏毒性与保护研究进展
被引量:1
摘要
15%-25%的乳腺癌患者存在HER-2基因扩增或过表达[1]。作为拮抗HER-2胞外受体的人源化单克隆抗体,曲妥珠单抗辅助治疗经5项随机对照临床试验证实可显著提高HER-2阳性乳腺癌患者的总生存(RR=0.66)及无瘤生存(RR=0.62)[2]。心脏毒性是曲妥珠单抗的主要不良反应,4.3%~17.3%的患者因此中断治疗[3]。
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2013年第1期84-86,共3页
Chinese Journal of Radiation Oncology
参考文献44
-
1Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled triM. Lancet,2007,369:29-36.
-
2Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and recta-analysis of randomized controlled trials. Oncologist, 2008,13:620-630.
-
3Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol,2011,6 : 189-195.
-
4Clarke M,Collins R,Darby S,et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet ,2005,366:2087-2106.
-
5Liang K,Lu Y,Jin W,et al. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther,2003,2 : 1113 - 1120.
-
6Horton JK, Halle J, Ferraro M, et al. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastnzumab: a phase Ⅱ trial. Int J Radiat Oncol Biol Phys,2010,76:998-1004.
-
7Negro A, Brar BK, Lee KF. Essential roles of HER-2/erbB2 in cardiac development and function. Recent Prog Horm Res,2004, 59:1-12.
-
8Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated eardiomyopathy. Nat Meal,2002,8:459-465.
-
9Lemmens K, Doggen K, De Keulenaer GW. Role of Neuregulin-1/ ErbB signaling in cardiovascular physiology and disease : implications for therapy of heart failure. Circulation, 2007,116 : 954-960.
-
10Uray IP, Connelly JH, Thomazy V, et al. Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transplant,2002,21:771-782.
二级参考文献42
-
1顾文栋,冯炎.放射线诱发心脏损伤的病理学机制[J].中华放射肿瘤学杂志,2004,13(2):110-112. 被引量:13
-
2Marks LB, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects, Int J Radiat Oncol Biol Phys,2005,63:214-223.
-
3Gyenes G, Fornander T, Carlens P, et al. Morbidity of ischemic heart disease in early breast cancer 15 - 20 years after adjuvantradiotherapy. Int J Radiat Oncol Biol Phys,1994,28:1235-1241.
-
4Gustavsson A, Bendahl P, Cwikiel M, et al. ,No serious late eardiae effects after adjuvant radiotherapy following masteetomy in premenopausal women with early breast eaneer. Int J Radiat Oneol Biol Phys, 1999,43:745-754.
-
5Breast cancer atlas for radiation therapy planning: consensus definitions [2010-06-10]. http://www, rtog. org/At|ases/ breastCancer/main, html.
-
6Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy : guidelines of the American Society of Clinical Oncology. J Clin Onco,2001,19 : 1539-1569.
-
7NCCN Clinical Practice Guidelines in Oncology: Breast Cancer [2010-06-20]. http://www, nccn. org/professionals/physician gls/PDF/breast, pdf.
-
8Marks LB, Hebert ME, Bentel G, et al. To treat or not to treat the internal mammary nodes: a possible compromise. Int J Radiat Oncol Bi01 Phys, 1994,29:903-909.
-
9van der Laan HP, Dolsma WV, van't Veld AA, et al. Comparison of normal tissue dose with three-dimensional conformal techniques for breast cancer irradiation including the internal mammary nodes. Int J Radiat Oncol Biol Phys,2005,63:1522-1530.
-
10Pierce LJ, Butler JB, Martel MK, et al. Postmastectomy radiotherapy of the chest wall: Dosimetric comparison of common techniques. Int J Radiat Oncol Biol Phys ,2002 ,52 : 1220-1230.
共引文献45
-
1黄店,原浩.乳腺现代放射治疗的体位固定技术与发展[J].世界最新医学信息文摘,2020(52):40-41. 被引量:2
-
2黄晓波,崔念基,张玉晶,卢泰祥,管迅行,刘孟忠.广东省放疗医师对乳腺癌改良根治术后放射治疗认识现状调查分析[J].肿瘤学杂志,2009,15(9):823-827.
-
3翟忠舟,赛亚非,樊彩霞,焦建峰,乔万海.乳腺癌根治术后放射治疗胸壁及腋窝的临床意义[J].现代肿瘤医学,2004,12(3):215-217. 被引量:1
-
4王玉,景娜.早期乳腺癌术后放疗的临床分析[J].中国肿瘤临床,2004,31(15):854-855. 被引量:2
-
5刘军.不同治疗方式对乳腺癌患者生活质量、局部区域复发率、远处转移率及生存率的影响:5年随访评价[J].中国临床康复,2005,9(26):26-27. 被引量:3
-
6惠周光,余子豪.我国乳腺癌改良根治术后放疗现状的调查分析[J].中华放射肿瘤学杂志,2005,14(6):471-475. 被引量:41
-
7胡洪林,敖睿,朱学强,贺盛光.乳腺癌术后胸壁复发39例临床分析[J].中国癌症杂志,2006,16(3):223-225. 被引量:15
-
8丛也彤,陈大伟,白岚,周银行,朴永峰,王溪,曲雅勤.乳腺癌术后胸壁电子线放射治疗的剂量分布[J].吉林大学学报(医学版),2006,32(5):832-834. 被引量:4
-
9王准,封巍,刘冠,郑晓,王跃珍.88例早期乳腺癌术后胸壁复发的多因素分析[J].实用肿瘤杂志,2006,21(5):453-456. 被引量:9
-
10丛也彤,张满英,金龙哲,张立萍.乳腺癌术后胸壁电子线放射治疗时肺受照剂量的分布[J].吉林医学,2006,27(10):1170-1171.
同被引文献8
-
1Gunter von Minckwitz,Kathrin Schwedler,Marcus Schmidt,Jana Barinoff,Christoph Mundhenke,Tanja Cufer,Eduard Maartense,Felix E. de Jongh,Klaus H. Baumann,Joachim Bischoff,Nadia Harbeck,Hans-Joachim Lück,Nicolai Maass,Christoph Zielinski,Michael Andersson,Robert C. Stein,Valentina Nekljudova,Sibylle Loibl.Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer[J].European Journal of Cancer.2011(15)
-
2郭予武,吴志海,钟俊勇.曲妥珠单抗联合紫杉醇治疗人表皮生长因子受体2阳性晚期乳腺癌的疗效[J].实用医学杂志,2012,28(15):2648-2649. 被引量:10
-
3吴涛,高娜,戴朝霞,蒋葵,张阳.长春瑞滨联合卡培他滨二、三线治疗晚期乳腺癌的临床观察[J].中国医师进修杂志,2012,35(27):70-73. 被引量:2
-
4姜华,李玺,黄勇,邱万寿,刘瑞磊,吴珏堃,黄泽楠,刘仁斌.吉西他滨联合长春瑞滨用于乳腺癌二线新辅助化学治疗的观察[J].新医学,2012,43(9):631-634. 被引量:5
-
5李春艳,张晟,刘艳,张瑾.三阴型乳腺癌159例临床病理特征分析[J].实用癌症杂志,2012,27(6):624-626. 被引量:9
-
6裘光贤,周兆春,石阳,崔舒晟.NP方案与GX方案二线治疗晚期乳腺癌的临床对比观察[J].肿瘤研究与临床,2012,24(12):809-812. 被引量:2
-
7边莉,江泽飞,王涛,宋金洁,郭芸菲,张会强,张少华,吴世凯,宋三泰.HER2阳性转移性乳腺癌多线靶向治疗耐药后再次使用曲妥珠单抗疗效及预后分析[J].中华医学杂志,2013,93(1):48-52. 被引量:11
-
8徐金明,黎可,陈轩,童富云,饶伟,徐美玲.曲妥珠单抗对HER2阳性乳腺癌患者术后辅助治疗的临床观察[J].重庆医学,2013,42(9):1025-1026. 被引量:10
二级引证文献5
-
1吴春燕.抗体-细胞毒分子耦合剂治疗对小分子酪氨酸激酶抑制剂耐药的HER-2阳性乳腺癌的效果[J].广东医学,2015,36(10):1602-1604. 被引量:2
-
2曹玉婷,王珊珊,杨德宣,李琳娜,袁守军.重组抗人表皮生长因子受体人源化单克隆抗体注射液对Bcap37人乳腺癌细胞生长的抑制作用[J].安徽医科大学学报,2016,51(11):1555-1558. 被引量:2
-
3黄玉琴.注射用曲妥珠单抗对人表皮生长因子受体2阳性晚期乳腺癌化疗患者血清肿瘤标志物及免疫功能的影响[J].中国综合临床,2017,33(8):748-752. 被引量:26
-
4宋泽军.曲妥珠单抗联合三苯氧胺治疗雌激素受体及人表皮生长因子受体2阳性晚期乳腺癌的效果观察[J].中国基层医药,2018,25(11):1424-1427. 被引量:4
-
5彭云,倪军.HER-2阳性乳腺癌辅助化疗后联合序贯曲妥珠单抗与卡培他滨的疗效分析[J].中国当代医药,2019,26(14):94-96. 被引量:5
-
1韩铭(综述),邓华瑜(审校).曲妥珠单抗在乳腺癌中的耐药机制研究进展[J].中华医学教育探索杂志,2011,10(9):1150-1152.
-
2任文晓,江泽飞,宋三泰.bevacizumab治疗乳腺癌的基础和临床研究[J].国际肿瘤学杂志,2006,33(8):600-602.
-
3赵红,李小龙,崔洁,冯谢敏,宋炜.曲妥珠单抗治疗胃癌的研究进展[J].延安大学学报(医学科学版),2012,10(1):25-27. 被引量:4
-
4流小舟,吴苏稼,施鑫.贝伐单抗在骨肉瘤治疗中的研究进展[J].江苏医药,2012,38(14):1698-1700.
-
5黄成兰,陆云海,俞智华.贝伐单抗联合卡培他滨治疗进展期胃癌15例初步观察[J].交通医学,2011,25(5):481-482. 被引量:4
-
6彭建柳,杨丽华.人源化单克隆抗体用于肿瘤分子靶向治疗的研究进展[J].现代医院,2009,9(5):8-11. 被引量:2
-
7栾雪梅,姚立新.曲妥珠单抗[J].中国处方药,2008(7):70-70. 被引量:2
-
8张一桥.赫赛汀联合紫杉醇治疗Her-2过度表达的转移性乳腺癌22例疗效观察[J].山东医药,2007,47(34):106-107. 被引量:5
-
9朱步东,任军.表皮生长因子受体2与乳腺癌治疗效果的预测[J].中华临床医师杂志(电子版),2010,4(3):18-24. 被引量:4
-
10万德森.贝伐单抗在转移性结直肠癌治疗中的应用[J].中国肿瘤临床,2009,36(23):1374-1376. 被引量:7